Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.51 |
| ▸ | PDE9A | O76083 | 1/20 | 0.51 |
| ▸ | PDE1A | P54750 | 1/20 | 0.51 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.51 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.51 |
| ▸ | CCR2 | P41597 | 2/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | YTHDF3 | Q7Z739 | 2/20 | 0.41 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.41 |
| ▸ | YTHDF1 | Q9BYJ9 | 2/20 | 0.41 |
| ▸ | YTHDF2 | Q9Y5A9 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751774 | 0.85 | CCR2 (0.44) | PDE5APDE9APDE1APDE1BPDE1C | |
| SCHEMBL5751373 | 0.83 | HCAR2 (0.42) | P2RX7HCAR2 | |
| SCHEMBL3494823 | 0.72 | PDE5A (0.71) | PDE5APDE9APDE1APDE1BPDE1C | |
| SCHEMBL13516703 | 0.71 | CCR2 (0.50) | PDE5APDE9APDE1APDE1BPDE1C | |
| SCHEMBL5749533 | 0.70 | CCR2 (0.47) | PDE5APDE9APDE1APDE1BPDE1C | |
| SCHEMBL5749688 | 0.69 | CCR2 (0.47) | PDE5APDE9APDE1APDE1BPDE1C | |
| SCHEMBL5751512 | 0.68 | CCR2 (0.44) | PDE5APDE9APDE1APDE1BPDE1C | |
| SCHEMBL3300276 | 0.67 | PNMT (0.65) | PNMT | |
| SCHEMBL19440676 | 0.67 | PNMT (0.46) | PDE5APDE9APDE1APDE1BPDE1C | |
| SCHEMBL5750625 | 0.66 | P2RX7 (0.57) | P2RX7MEN1ALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299361-B1 | PYRAZOLE DERIVATIVES | PFIZER LTD (GB) | 2006-07-19 | — | — | EP | claimed |
| EP-1299361-A1 | PYRAZOLE DERIVATIVES | Pfizer Limited (GB) | 2003-04-09 | — | — | EP | claimed |
| WO-2002004424-A9 | PYRAZOLE DERIVATIVES | PFIZER LTD (GB) | 2002-12-12 | — | — | WO | claimed |
| US-20020032184-A1 | Pyrazole derivatives | PFIZER INC. | 2002-03-14 | — | — | US | claimed |
| WO-2002004424-A1 | PYRAZOLE DERIVATIVES | PFIZER LIMITED (GB) | 2002-01-17 | — | — | WO | claimed |
| US-7141585-B2 | Pyrazole derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1299361-B1 | PYRAZOLE DERIVATIVES | PFIZER LTD (GB) | 2006-07-19 | — | — | EP | disclosed |
| US-20040209862-A1 | Pyrazole derivatives | PFIZER, INC. | 2004-10-21 | — | — | US | disclosed |
| US-6750230-B2 | use treating Human Immunodeficiency Virus (HIV) , or genetically related retroviral, infection or a resulting acquired immunodeficiency syndrome (AIDS); 2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethanol for example; reverse transcriptase inhibitors | PFIZER, INC. | 2004-06-15 | — | — | US | disclosed |
| EP-1299361-A1 | PYRAZOLE DERIVATIVES | Pfizer Limited (GB) | 2003-04-09 | — | — | EP | disclosed |
| US-20020032184-A1 | Pyrazole derivatives | PFIZER INC. | 2002-03-14 | — | — | US | disclosed |
| WO-2002004424-A1 | PYRAZOLE DERIVATIVES | PFIZER LIMITED (GB) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032184-A1 | Pyrazole derivatives | POLRMT, TPMT, CYP3A43 | PDE5A 1072/4885PDE9A 2785/4885PDE1A 3153/4885 |
| US-20040209862-A1 | Pyrazole derivatives | POLRMT, TPMT, CYP3A43 | PDE5A 1072/4885PDE9A 2785/4885PDE1A 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.